The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
22h
Livewire Markets on MSNThe 4 biotech firms the experts are most excited aboutThe biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.
1d
Zacks Investment Research on MSNNovo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on March 21 and set a price target of ...
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Investing.com -- Morgan Stanley upgraded its rating on Zealand Pharma (NASDAQ: ZEAL) shares to Overweight from Equal Weight, ...
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results